14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
LYRA vs BAX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Baxter International Inc. (BAX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas BAX carries 46.5/100 (HOLD) at $25.83 (12.5x Forward P/E, 7.6% operating margin).
Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. BAX 46.5/100 HOLD), BAX captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (7.6% vs. -25032.0% operating margin) and revenue trajectory (+5.0% vs. -87.2% YoY).
Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile BAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Instruments & Supplies value chain with $13.4B market capitalization and 7.6% operating margin.
OpEx & R&D Reinvestment25.8% of Rev ($3.00B)
90D Engineering Disclosures0 Published
Investor FAQ LYRA vs BAX Key Questions & Quantitative Answers
As of Nov 17, 2026, Baxter International Inc. (BAX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas BAX carries 46.5/100 (HOLD) at $25.83 (12.5x Forward P/E, 7.6% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. BAX 46.5/100 HOLD), BAX captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (7.6% vs. -25032.0% operating margin) and revenue trajectory (+5.0% vs. -87.2% YoY). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile BAX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BAX leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with BAX at +5.0% YoY revenue growth and +36.8% YoY earnings growth on $11.6B TTM revenue (33.4% gross margin, 7.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LYRA cumulative revenue shifted N/A while BAX shifted +1.3%. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus 25.8% of Rev ($3.00B) (0 disclosures) for BAX.
BAX screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas BAX trades at 12.5x Forward P/E, 12.2x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (9.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus BAX (-9.0% ROE) capital efficiency.
In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, BAX carries 48.4% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.15x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.95β · 47% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.